AL 335/odalasvir/simeprevir - Janssen/Medivir

Drug Profile

AL 335/odalasvir/simeprevir - Janssen/Medivir

Alternative Names: AL-335/odalasvir/simeprevir - Janssen/Medivir; JNJ-4178; odalasvir/simeprevir/AL-335 - Janssen/Medivir; simeprevir/AL-335/odalasvir - Janssen/Medivir

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Janssen; Medivir AB
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 28 Nov 2016 Phase-II clinical trials in Hepatitis C (Treatment-experienced) in Germany (PO) after November 2016 (NCT02765490)
  • 28 Nov 2016 Phase-II clinical trials in Hepatitis C (Treatment-naive) in Germany (PO) after November 2016 (NCT02765490)
  • 28 Nov 2016 Phase-II clinical trials in Hepatitis C (Treatment-experienced) in Canada (PO) (NCT02765490; 9207736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top